The filing discloses the approval of compensatory arrangements (stock-based compensation) for existing officers, not a change in management personnel.

Results of Operations and Financial Condition. On August 11, 2026, Imunon, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On August 4, 2026, Imunon, Inc. announced it would hold a conference call on August 11, 2026 to discuss its financial results for the quarter ended June 30, 2026 and provide a business update. A live webcast of the call will also be…

interim Chief Financial Officer — Jeffrey Church: Mr. Church retired from his position as interim Chief Financial Officer and was succeeded by Josh Blacher.

The filing pertains to an amendment of the stock incentive plan, not a management change.

Entry into a Material Definitive Agreement. On June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares (the “ Preferred Shares ”) of the Company’s Series A Preferred Stock, par value $0.01 per share (the “ Series A Preferred Stock ”), at a price of $10,000 per share,…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant. The information contained in

by reference. The Preferred Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”).

Results of Operations and Financial Condition. On May 12, 2026, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On May 5, 2026, Imunon, Inc. announced it would hold a conference call on May 12, 2026 to discuss its financial results for the quarter ended March 31, 2026 and provide a business update. The conference call will also be broadcast liv…

The company entered into change of control agreements with certain executives providing severance benefits.

Results of Operations and Financial Condition. On March 31, 2026, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On March 24, 2026, Imunon, Inc. announced it would hold a conference call on March 31, 2026 to discuss its financial results for the year ended December 31, 2025 and provide a business update. The conference call will also be broadc…

Other Events. On March 23, 2026, Imunon, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $7,000,000 of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Compa…

Executive Vice President and Chief Scientific Officer — Khursheed Anwer: Dr. Khursheed Anwer is retiring from his role as Executive Vice President and Chief Scientific Officer.

interim Chief Financial Officer — Kimberly Graper: Ms. Graper resigned to pursue another career opportunity, and Mr. Jeffrey Church was appointed as the new interim Chief Financial Officer.

Entry into a Material Definitive Agreement. On December 29, 2025, Imunon, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering (the “Offering”) of (i) 330,000 shares (the “Shares”) of its common stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-funded Warrants”) in lieu of Shares, to the…

Results of Operations and Financial Condition. On November 13, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On November 6, 2025, Imunon, Inc. announced it would hold a conference call on November 13, 2025 to discuss its financial results for the quarter ended September 30, 2025 and provide a business update. The conference call wil…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

Results of Operations and Financial Condition. On August 5, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On July 29, 2025, Imunon, Inc. announced it would hold a conference call on August 5, 2025 to discuss its financial results for the quarter ended June 30, 2025 and provide a business update. The conference call will also be broadcast…

Other Events. On July 28, 2025, Imunon, Inc. (the “Company”), issued a press release announcing that the Company’s Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock, par value $0.01 per share (the “Common Stock”), and per each common stock equivalent with dividend rights. The Board of Directors has fixed August 7, 2025 as the record date (the “Record Date”) for the Stock…

or Item 9.01; and ● Description of Securities of the Company, incorporated herein by reference to Exhibit 4.7 to the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2024. 19 In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering (excluding any information furnished rather than filed), shall be deemed to be incorporated by reference into this prospectus. An…

Other Events. On July 22, 2025, Imunon, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $4,500,000 of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Compan…

The filing is about an amendment to the stock incentive plan, not a management change.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Delisting Notice As previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price…

Material Modification to Rights of Security Holders. At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Imunon, Inc. (the “Company”) held on July 11, 2025, and as further described in

interim Chief Financial Officer — David Gaiero: The termination of David Gaiero as the interim Chief Financial Officer and his consulting agreement with Monomoy Advisors, LLC.

Other Events. As previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Ma…